Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 6/20 | 0.56 |
| ▸ | NT5E | P21589 | 3/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.54 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469227 | 1.00 | RNASEL (0.56) | RNASELNT5EP2RY1P2RY11CA5A | |
| SCHEMBL8426440 | 0.89 | RNASEL (0.70) | RNASELNT5EP2RY1P2RY11CA5A | |
| SCHEMBL16619900 | 0.86 | ADORA3 (0.64) | RNASELNT5EIMPDH2IMPDH1ADORA1 | |
| SCHEMBL5690848 | 0.84 | P2RY1 (0.63) | NT5EP2RY1P2RY11TAS1R3TAS1R1 | |
| SCHEMBL1898711 | 0.82 | LMNA (0.62) | NT5EADORA1 | |
| SCHEMBL1898718 | 0.82 | LMNA (0.62) | NT5EADORA1 | |
| Phosphoric Acid SCHEMBL30965379 | 0.82 | P2RY1 (0.66) | NT5EP2RY1P2RY11TAS1R3TAS1R1 | |
| SCHEMBL8862433 | 0.81 | P2RY1 (0.62) | NT5EP2RY1P2RY11CA5A | |
| SCHEMBL188740 | 0.80 | CA5A (0.68) | RNASELNT5EP2RY1P2RY11CA5A | |
| SCHEMBL24049291 | 0.79 | NT5E (0.54) | NT5EP2RY1P2RY11CA5ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042537-B2 | Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects | BioVaxys Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11717563-B2 | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2023-08-08 | — | — | US | disclosed |
| US-20220347296-A1 | METHODS OF USING LOW DOSE VOLUME B-CELL EPITOPE COMPOSITIONS FOR INDUCING AN ANTIBODY IMMUNE RESPONSE IN HUMAN SUBJECTS | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-11-03 | — | — | US | disclosed |
| US-11406705-B2 | Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20220143165-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-05-12 | — | — | US | disclosed |
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-03-01 | — | — | US | disclosed |
| US-20220001010-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11160861-B2 | Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2021-11-02 | — | — | US | disclosed |
| US-20190290743-A1 | Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2019-09-26 | — | — | US | disclosed |
| EP-3518963-A1 | METHODS OF USING LOW DOSE VOLUME B-CELL EPITOPE COMPOSITIONS FOR INDUCING AN ANTIBODY IMMUNE RESPONSE IN HUMAN SUBJECTS | ImmunoVaccine Technologies Inc. (CA) | 2019-08-07 | — | — | EP | disclosed |
| US-20190151428-A1 | Vaccine Compositions Comprising an Amphipathic Compound, a Neoantigen and a Hydrophobic Carrier, and Methods of Use Thereof | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| EP-3452083-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | ImmunoVaccine Technologies Inc. (CA) | 2019-03-13 | — | — | EP | disclosed |
| US-20180339039-A1 | Adjuvanting Systems and Water-Free Vaccine Compositions Comprising a PolyI:C Polynucleotide Adjuvant and a Lipid-based Adjuvant | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2018-11-29 | — | — | US | disclosed |
| EP-3377099-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | ImmunoVaccine Technologies Inc. (CA) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018058230-A1 | METHODS OF USING LOW DOSE VOLUME B-CELL EPITOPE COMPOSITIONS FOR INDUCING AN ANTIBODY IMMUNE RESPONSE IN HUMAN SUBJECTS | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017190242-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2017-11-09 | — | — | WO | disclosed |
| EP-2296696-B1 | COMPOSITIONS COMPRISING LIPOSOMES, AN ANTIGEN, A POLYNUCLEOTIDE AND A CARRIER COMPRISING A CONTINUOUS PHASE OF A HYDROPHOBIC SUBSTANCE | IMMUNOVACCINE TECHNOLOGIES INC (CA) | 2014-08-27 | — | — | EP | disclosed |
| US-20110070298-A1 | Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| EP-2296696-A1 | COMPOSITIONS COMPRISING LIPOSOMES, AN ANTIGEN, A POLYNUCLEOTIDE AND A CARRIER COMPRISING A CONTINUOUS PHASE OF A HYDROPHOBIC SUBSTANCE | ImmunoVaccine Technologies Inc. (CA) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009146523-A1 | COMPOSITIONS COMPRISING LIPOSOMES, AN ANTIGEN, A POLYNUCLEOTIDE AND A CARRIER COMPRISING A CONTINUOUS PHASE OF A HYDROPHOBIC SUBSTANCE | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | TP53, HLA-DRB1, CD74 | RNASEL 3450/4885NT5E 3354/4885P2RY1 4611/4885 |
| US-20190151428-A1 | Vaccine Compositions Comprising an Amphipathic Compound, a Neoantigen and a Hydrophobic Carrier, and Methods of Use Thereof | TP53, HLA-DRB1, CD74 | RNASEL 3450/4885NT5E 3354/4885P2RY1 4611/4885 |
| US-20220143165-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | TP53, HLA-DRB1, CD74 | RNASEL 3450/4885NT5E 3354/4885P2RY1 4611/4885 |
| US-11160861-B2 | Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant | TLR3, PLA2G2C, TLR9 | RNASEL 305/4885NT5E 631/4885P2RY1 1464/4885 |
| US-20220001010-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | TLR3, PLA2G2C, TLR9 | RNASEL 305/4885NT5E 631/4885P2RY1 1464/4885 |
| US-20180339039-A1 | Adjuvanting Systems and Water-Free Vaccine Compositions Comprising a PolyI:C Polynucleotide Adjuvant and a Lipid-based Adjuvant | TLR3, PLA2G2C, TLR9 | RNASEL 305/4885NT5E 631/4885P2RY1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.